Compare EDAP & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDAP | TKNO |
|---|---|---|
| Founded | 1979 | 1996 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.9M | 138.1M |
| IPO Year | 1998 | 2021 |
| Metric | EDAP | TKNO |
|---|---|---|
| Price | $3.36 | $3.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 23.9K | ★ 104.0K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,527,000.00 | $40,520,000.00 |
| Revenue This Year | N/A | $8.27 |
| Revenue Next Year | $6.13 | $13.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.63 | ★ 7.35 |
| 52 Week Low | $1.21 | $1.91 |
| 52 Week High | $5.05 | $7.48 |
| Indicator | EDAP | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 58.30 |
| Support Level | $3.13 | $3.01 |
| Resistance Level | $3.44 | $3.25 |
| Average True Range (ATR) | 0.21 | 0.26 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 37.93 | 77.65 |
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.